Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784913 | 1.00 | AKT1 (0.48) | AKT1MEN1KMT2ACTSSCTSL | |
| SCHEMBL23035088 | 0.91 | AKT1 (0.50) | AKT1MEN1KMT2ACTSSCTSL | |
| SCHEMBL23035087 | 0.91 | AKT1 (0.50) | AKT1MEN1KMT2ACTSSCTSL | |
| SCHEMBL23035155 | 0.90 | SIGMAR1 (0.44) | AKT1CTSSCTSLCTSBSYK | |
| SCHEMBL20578332 | 0.89 | GAA (0.43) | AKT1 | |
| SCHEMBL20578054 | 0.89 | CACNA1B (0.42) | AKT1MEN1KMT2A | |
| SCHEMBL20578055 | 0.89 | CACNA1B (0.42) | AKT1MEN1KMT2A | |
| SCHEMBL20578333 | 0.89 | GAA (0.43) | AKT1 | |
| SCHEMBL20578346 | 0.87 | CTSS (0.45) | AKT1MEN1KMT2ACTSSCTSK | |
| SCHEMBL20578347 | 0.87 | CTSS (0.45) | AKT1MEN1KMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602810-B | Suvorexane intermediate compound and preparation method thereof | 浙江华海药业股份有限公司 | 2021-11-09 | — | — | CN | claimed |
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | claimed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | claimed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | claimed |
| CN-108602810-B | Suvorexane intermediate compound and preparation method thereof | 浙江华海药业股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-107021955-B | Suvorexane intermediate compound and preparation method thereof | 上海奥博生物医药股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017133620-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | 浙江华海药业股份有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2016085784-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085784-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | AKT1 3470/4885MEN1 1001/4885KMT2A 408/4885 |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | COMT, KMO, CYP4B1 | AKT1 1391/4885MEN1 1102/4885KMT2A 89/4885 |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | COMT, KMO, CYP4B1 | AKT1 1391/4885MEN1 1102/4885KMT2A 89/4885 |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | AKT1 3470/4885MEN1 1001/4885KMT2A 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.